3 Tertiary Care Hospitals, Preventive Health Testing and Large Hospital Chains Stocks With a Strong Future Roadmap: Global Health, Thyrocare Technologies and Apollo Hospitals Enterprise

Hospital and preventive diagnostics stocks let investors follow providers of complex treatment and the labs that support early detection. Global Health, Thyrocare Technologies and Apollo Hospitals Enterprise cover tertiary care hospitals, preventive health testing and one of the largest hospital chains.

This list covers three hospital and preventive diagnostics stocks with complete current figures: Global Health, Thyrocare Technologies and Apollo Hospitals Enterprise. Every figure comes from the latest reported financials and the 21 October 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

What Are Hospital and Preventive Diagnostics Stocks?

Hospital and preventive diagnostics stocks are listed companies that run large hospitals and diagnostic labs. Their earnings depend on bed capacity, occupancy, test volumes and the share of complex procedures.

Hospital and Preventive Diagnostics Stocks at a Glance

On valuation, Thyrocare Technologies and Apollo Hospitals Enterprise trade at a P/E below the industry P/E, while Global Health trades above it, which reflects the growth the market already expects. Readers comparing hospital and preventive diagnostics stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in hospital and preventive diagnostics stocks can use the coming numbers to test whether growth is holding.

Why Do Hospital and Preventive Diagnostics Stocks Have a Strong Roadmap in India?

Hospital and preventive diagnostics stocks have a strong roadmap in India because demand for advanced treatment and early testing is rising faster than the supply of organised capacity.

• Complex procedures. Tertiary care lifts revenue per patient.
• Health awareness. More people opt for regular preventive tests.
• Digital reach. Online booking and home collection widen the customer base.

Why Global Health Features Among These Hospital and Preventive Diagnostics Stocks

Among the hospital and preventive diagnostics stocks on this list, Global Health, which operates the Medanta brand, runs tertiary-care hospitals led by its flagship campus in Gurugram, along with facilities in Lucknow, Patna, Ranchi, Indore and Noida.

The company has a return on equity of 14.1%, a debt to equity ratio of 0.30 and a market capitalisation of Rs 33,277 crore. The stock trades at a P/E of 60.3, above the industry P/E of 59.6.

Revenue rose from Rs 2,206 crore in FY22 to Rs 4,509 crore in FY26, a compound annual growth rate of 19.6%. Net profit grew from Rs 196 crore in FY22 to Rs 554 crore in FY26, which works out to a compound annual growth rate of 29.6%. In the June 2026 quarter, revenue grew 26.1% year on year to Rs 1,326 crore.

Roadmap: Management is widening its reach in Tier 2 cities while adding capacity at the Gurugram campus. A broader doctor base and a rising share of complex procedures such as cardiac and transplant care support the earnings mix as new facilities mature.

What to watch: Watch the ramp-up speed of newer hospitals and the pace of doctor additions at each site.

Why Thyrocare Technologies Features Among These Hospital and Preventive Diagnostics Stocks

Among the north India hospital shares on this list, Thyrocare Technologies runs a centralised, high-volume testing laboratory in Navi Mumbai and collects samples through a wide partner network of diagnostic centres, pharmacies and franchisees across India.

Revenue rose from Rs 618 crore in FY22 to Rs 846 crore in FY26, a compound annual growth rate of 8.2%. Net profit grew from Rs 64.4 crore in FY23 to Rs 163 crore in FY26, which works out to a compound annual growth rate of 36.3%.

In the June 2026 quarter, revenue grew 23.5% year on year to Rs 244 crore, while net profit rose 34.1% to Rs 51.3 crore. The company has a return on equity of 27.9%, a debt to equity ratio of 0.09 and a market capitalisation of Rs 7,501 crore. The stock trades at a P/E of 42.6, below the industry P/E of 59.6.

Roadmap: The centralised model gives it a low unit cost per test, and the company is adding wellness and preventive health packages along with a growing share of direct-to-consumer bookings. Its partner-led channel lets it scale volumes without building its own collection centres.

What to watch: Track growth in test volume per day and the share of revenue from preventive health packages.

Why Apollo Hospitals Enterprise Features Among These Hospital and Preventive Diagnostics Stocks

Among the three companies on this list, Apollo Hospitals Enterprise is India's largest private healthcare group, running a network of hospitals along with a pharmacy chain, diagnostics, primary care clinics and a digital health platform.

In the June 2026 quarter, revenue grew 20.6% year on year to Rs 7,092 crore, while net profit rose 38.4% to Rs 610 crore. Revenue rose from Rs 14,741 crore in FY22 to Rs 25,420 crore in FY26, a compound annual growth rate of 14.6%.

Net profit grew from Rs 1,101 crore in FY22 to Rs 2,003 crore in FY26, which works out to a compound annual growth rate of 16.1%. The company has a return on equity of 20.5%, a debt to equity ratio of 0.90 and a market capitalisation of Rs 110,757 crore. The stock trades at a P/E of 51.0, below the industry P/E of 59.6.

Roadmap: The company is adding hospital beds in proven cities while growing its pharmacy and digital businesses, which broaden its reach beyond inpatient care. A strong brand in complex treatment and a wide patient base support steady occupancy.

What to watch: Track bed additions and occupancy and the growth of the pharmacy and digital health businesses.

Global Health vs Thyrocare Technologies vs Apollo Hospitals Enterprise on Key Financials

The table below sets the three hospital and preventive diagnostics stocks side by side on revenue, profit and margin, using reported figures.

Thyrocare Technologies posts the highest return on equity in this group at 27.9%. Apollo Hospitals Enterprise has the largest FY26 revenue at Rs 25,420 crore, and Global Health shows the fastest revenue growth with a 19.6% compound annual rate. A useful habit with hospital and preventive diagnostics stocks is to check each new quarterly result against the capacity plans the company described earlier.

The June 2026 quarter, the latest reported, gives a fresh read on momentum:

Key Risks to Check Before Investing in Hospital and Preventive Diagnostics Stocks

Every theme carries risks that deserve a check before any decision. For these hospital and preventive diagnostics stocks, the main points are: Long-term north India hospital shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.

• Ramp-up timing. New hospitals take time to reach stable utilisation.
• Doctor availability. Expert doctors are central to growth and hard to attract.
• Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.

Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.

Use the Univest Stock Screener to filter hospital and preventive diagnostics stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.

Final Thoughts on Hospital and Preventive Diagnostics Stocks

Hospital and preventive diagnostics stocks reward investors who follow bed additions, occupancy and test volumes together. Global Health, Thyrocare Technologies and Apollo Hospitals Enterprise each serve a growing patient base. Based on the 21 October 2026 close, Global Health trades at Rs 1,232.4, Thyrocare Technologies at Rs 456.2 and Apollo Hospitals Enterprise at Rs 7,600. Valuation matters as much as growth, so compare each company's P/E with its industry P/E before adding any of these hospital and preventive diagnostics stocks to a watchlist.

Download the Univest iOS App or Univest Android App to track hospital and preventive diagnostics stocks, set price alerts and get research-backed stock ideas.

What are hospital and preventive diagnostics stocks?

Ans. Hospital and preventive diagnostics stocks are listed companies that run large hospitals and diagnostic labs. Their earnings depend on bed capacity, occupancy, test volumes and the share of complex procedures. This list looks at three of them, Global Health, Thyrocare Technologies and Apollo Hospitals Enterprise, using reported FY22 to FY26 financials and the 21 October 2026 closing prices.

Which hospital and preventive diagnostics stocks are covered in this list?

Ans. This list covers Global Health, Thyrocare Technologies and Apollo Hospitals Enterprise. Based on the 21 October 2026 close, Global Health traded at Rs 1,232.4, Thyrocare Technologies at Rs 456.2 and Apollo Hospitals Enterprise at Rs 7,600. Their return on equity ranges from 14.1% to 27.9%, and their revenue compound annual growth from FY22 to FY26 ranges from 8.2% to 19.6%.

Why do hospital and preventive diagnostics stocks have a strong future roadmap in India?

Ans. Hospital and preventive diagnostics stocks have a strong roadmap in India because demand for advanced treatment and early testing is rising faster than the supply of organised capacity. The main drivers are as follows. Complex procedures. Tertiary care lifts revenue per patient. Health awareness. More people opt for regular preventive tests. Digital reach. Online booking and home collection widen the customer base. Together these factors give the companies on this list a visible path for growth over the coming years.

How has Global Health performed financially?

Ans. Revenue rose from Rs 2,206 crore in FY22 to Rs 4,509 crore in FY26, a compound annual growth rate of 19.6%. Net profit grew from Rs 196 crore in FY22 to Rs 554 crore in FY26, which works out to a compound annual growth rate of 29.6%. In the June 2026 quarter, revenue grew 26.1% year on year to Rs 1,326 crore. The company has a return on equity of 14.1%, a debt to equity ratio of 0.30 and a market capitalisation of Rs 33,277 crore. The stock trades at a P/E of 60.3, above the industry P/E of 59.6. Looking ahead, management is widening its reach in Tier 2 cities while adding capacity at the Gurugram campus. A broader doctor base and a rising share of complex procedures such as cardiac and transplant care support the earnings mix as new facilities mature.

How has Thyrocare Technologies performed financially?

Ans. Revenue rose from Rs 618 crore in FY22 to Rs 846 crore in FY26, a compound annual growth rate of 8.2%. Net profit grew from Rs 64.4 crore in FY23 to Rs 163 crore in FY26, which works out to a compound annual growth rate of 36.3%. In the June 2026 quarter, revenue grew 23.5% year on year to Rs 244 crore, while net profit rose 34.1% to Rs 51.3 crore. The company has a return on equity of 27.9%, a debt to equity ratio of 0.09 and a market capitalisation of Rs 7,501 crore. The stock trades at a P/E of 42.6, below the industry P/E of 59.6. Looking ahead, the centralised model gives it a low unit cost per test, and the company is adding wellness and preventive health packages along with a growing share of direct-to-consumer bookings. Its partner-led channel lets it scale volumes without building its own collection centres.

How has Apollo Hospitals Enterprise performed financially?

Ans. Revenue rose from Rs 14,741 crore in FY22 to Rs 25,420 crore in FY26, a compound annual growth rate of 14.6%. Net profit grew from Rs 1,101 crore in FY22 to Rs 2,003 crore in FY26, which works out to a compound annual growth rate of 16.1%. In the June 2026 quarter, revenue grew 20.6% year on year to Rs 7,092 crore, while net profit rose 38.4% to Rs 610 crore. The company has a return on equity of 20.5%, a debt to equity ratio of 0.90 and a market capitalisation of Rs 110,757 crore. The stock trades at a P/E of 51.0, below the industry P/E of 59.6. Looking ahead, the company is adding hospital beds in proven cities while growing its pharmacy and digital businesses, which broaden its reach beyond inpatient care. A strong brand in complex treatment and a wide patient base support steady occupancy.

What risks should investors check before buying hospital and preventive diagnostics stocks?

Ans. Investors should check a few risks before buying hospital and preventive diagnostics stocks. Ramp-up timing. New hospitals take time to reach stable utilisation. Doctor availability. Expert doctors are central to growth and hard to attract. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.

Is this list of hospital and preventive diagnostics stocks investment advice?

Ans. No. This article is educational and uses publicly available data as of the 21 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.